Neximmune Inc [NASDAQ: NEXI] jumped around 3.95 points on Monday, while shares priced at $9.30 at the close of the session, up 73.83%. The company report on October 24, 2023 at 8:00 AM that NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes.
A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes.
Compared to the average trading volume of 1.91M shares, NEXI reached a trading volume of 8022317 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Neximmune Inc [NEXI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NEXI shares is $125.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NEXI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Neximmune Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 01, 2021.
The Average True Range (ATR) for Neximmune Inc is set at 1.97 The Price to Book ratio for the last quarter was 0.05, with the Price to Cash per share for the same quarter was set at 8.55.
How has NEXI stock performed recently?
Neximmune Inc [NEXI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 64.31. With this latest performance, NEXI shares gained by 339.30% in over the last four-week period, additionally plugging by 24.41% over the last 6 months – not to mention a drop of -1.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NEXI stock in for the last two-week period is set at 62.62, with the RSI for the last a single of trading hit 65.04, and the three-weeks RSI is set at 61.38 for Neximmune Inc [NEXI]. The present Moving Average for the last 50 days of trading for this stock 4.55, while it was recorded at 5.99 for the last single week of trading, and 6.05 for the last 200 days.
Neximmune Inc [NEXI]: Deeper insight into the fundamentals
Neximmune Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.66 and a Current Ratio set at 1.66.
Earnings analysis for Neximmune Inc [NEXI]
With the latest financial reports released by the company, Neximmune Inc posted -15/share EPS, while the average EPS was predicted by analysts to be reported at -17.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NEXI.
Insider trade positions for Neximmune Inc [NEXI]
The top three institutional holders of NEXI stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in NEXI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in NEXI stock with ownership which is approximately 5.8325%.